From August 29 to 30, the 2024 Nanase Summit Forum was held in Zhongyuan Medical Science City, Zhengzhou, China. The forum was hosted by Zhongyuan Nanomase Laboratory, and Professor Yan Xiyun, Academician of Chinese Academy of Sciences, served as the chairman of the forum. Dr. Zhao Lijun, Director of R&D Department of our company, was honored to participate in the forum and reported on the cooperation projects and research progress.

Minister Zhao Lijun reported on the clinical research of CAR T cell therapy for acute myeloid leukemia. She detailed the latest research results of the Shenzhen Cell Valley R&D team in the CAR T cell treatment of acute myeloid leukemia project, showing its significant advantages in improving efficacy and reducing side effects in a variety of forms.

Academician Yan Xiyun and other experts at the meeting affirmed and appreciated the keynote report made by Minister Zhao Lijun, and agreed that the process of related work such as Zhongyuan Nanase Laboratory and Shenzhen Cell Valley research and development project should be accelerated. The two sides said they will jointly establish a joint venture company in Zhengzhou, Henan Province, to promote the implementation of cell therapy projects, and aim to start clinical trials at Ludaopei Hospital in the first half of 2025. They firmly believe that this cooperation will inject new vitality into the development of biotechnology industry in the Central Plains region and even the whole country, and look forward to the near future, cell therapy technology can bring well-being to more patients and make greater contributions to human health.